Evidence map›Paper›PMID 36685298›Full record

ArticleSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society2023

Construction and stable gene expression of AGR2xPD1 bi-specific antibody that enhances attachment between

Debmalya Roy, Guo-Song Liu, Aru Zeling Wang, Bingjie Zhou, Fakhar-Un-Nisa Yunus, Ghulam Raza, Siva Bharath Merugu, Dhahiri Saidi Mashausi, Dawei Li, Bo Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Debmalya RoySchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Guo-Song LiuSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Aru Zeling WangSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Bingjie ZhouSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Fakhar-Un-Nisa YunusSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Ghulam RazaSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Siva Bharath MeruguSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Dhahiri Saidi MashausiSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Dawei LiSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.
Bo ZhaoSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There has been a substantial and consistent rise in the number of clinical trials to develop advanced and potent bispecific antibodies (BsAb) over the past two decades with multiple targets to improve the efficacy or tissue specificity of monoclonal antibodies (mAb) treatment for diseases with multiple determining factors or widely-expressed targets. In this study, we designed and synthesized BsAb AGR2xPD1 targeting extracellular AGR2, a paracrine signal, and PD1, an immune checkpoint protein. Our design is intended to use AGR2 binding to guide PD1 targeting for AGR2

Indexed as

AGR2xPD1 BsAbBiotechnologyBispecific antibodycytotoxic CD8+T-cellsDrug targetingLung cancerPharmaceutical

Identifiers

PMID36685298
PMCPMC9845114

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.